Risk factors for acquisition of colistin-resistant
Anti-Bacterial Agents
/ pharmacology
Bacterial Proteins
Clone Cells
Colistin
/ pharmacology
Cross Infection
/ epidemiology
Drug Resistance, Bacterial
Epidemics
France
/ epidemiology
Hospitals
Humans
Klebsiella Infections
/ drug therapy
Klebsiella pneumoniae
/ genetics
Male
Microbial Sensitivity Tests
Retrospective Studies
Risk Factors
Klebsiella pneumoniae
ST307
colistin resistance
outbreak
risk factors
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
entrez:
28
5
2021
pubmed:
29
5
2021
medline:
29
6
2021
Statut:
ppublish
Résumé
BackgroundFrance is a low prevalence country for colistin resistance. Molecular and epidemiological events contributing to the emergence of resistance to colistin, one of the 'last-resort' antibiotics to treat multidrug-resistant Gram-negative infections, are important to investigate.AimThis retrospective (2014 to 2017) observational study aimed to identify risk factors associated with acquisition of colistin-resistant
Identifiants
pubmed: 34047270
doi: 10.2807/1560-7917.ES.2021.26.21.2000022
pmc: PMC8161728
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
Colistin
Z67X93HJG1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Références
Bioinformatics. 2015 Nov 15;31(22):3691-3
pubmed: 26198102
Int J Antimicrob Agents. 2014 Dec;44(6):500-7
pubmed: 25264127
Front Microbiol. 2014 Oct 20;5:551
pubmed: 25368610
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32747358
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6969-6972
pubmed: 27620478
J Antimicrob Chemother. 2019 Mar 1;74(3):577-581
pubmed: 30517666
Microb Drug Resist. 2021 Apr 9;:
pubmed: 33835874
Antimicrob Agents Chemother. 2015 May;59(5):2909-13
pubmed: 25691646
J Clin Microbiol. 2010 Jun;48(6):2271-4
pubmed: 20375234
Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):395-407
pubmed: 30515637
J Antimicrob Chemother. 2017 Oct 1;72(10):2715-2721
pubmed: 29091215
Microb Drug Resist. 2013 Aug;19(4):295-7
pubmed: 23530541
Clin Microbiol Infect. 2013 Jan;19(1):E23-E30
pubmed: 23137235
Emerg Infect Dis. 2020 Jun;26(6):1212-1220
pubmed: 32441629
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28242665
Infection. 2014 Oct;42(5):883-90
pubmed: 25008195
Int J Antimicrob Agents. 2016 Jan;47(1):1-3
pubmed: 26712133
J Med Microbiol. 2017 Jul;66(7):959-964
pubmed: 28741998
J Antimicrob Chemother. 2016 Apr;71(4):887-96
pubmed: 26769896
J Glob Antimicrob Resist. 2019 Sep;18:225-229
pubmed: 31201994
J Bacteriol. 2008 Sep;190(18):6276-9
pubmed: 18567659
Int J Antimicrob Agents. 2020 Sep;56(3):106045
pubmed: 32522673
Euro Surveill. 2016 Sep 15;21(37):
pubmed: 27685838
Int J Antimicrob Agents. 2016 Dec;48(6):583-591
pubmed: 27524102
Clin Microbiol Infect. 2015 Dec;21(12):1106.e1-8
pubmed: 26278669
Nat Microbiol. 2019 Nov;4(11):1919-1929
pubmed: 31358985